Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00619684 · OUTCOME

TTP

Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant · Source last updated 2017-05-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
Full Range
Time frame
Up to 9 years

What was measured

Time to Progression (TTP): Time from start of therapy to meeting the definition of Progressive Disease (PD). PD: 25% increase compared to the lowest value of: * Serum MP (absolute increase at least ≥ 0.5 g/dl) * Or: Urine MP (absolute increase at least \> 200 mg/24h) * Or: for patients without measurable MP, Serum Free Light Chain test: the difference between involved and uninvolved FLC levels (absolute increase at least \>100 mg/L)

Analysis population: Patients who developed Progressive Disease while on lenalidomide treatment

Groups in this outcome

Treatment (Lenalidomide)

Patients receive lenalidomide PO on days 1-21. Courses repeat every 28 days for 2 years or longer in the absence of disease progression or unacceptable toxicity. lenalidomide: Given PO

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Lenalidomide)10

Reported measurements

Source class 1
Values in Months · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Treatment (Lenalidomide)8.5Not reported1.243Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1.2
        upper Limit
        43
        value
        8.5
denoms
  1. counts
    1. group Id
      OG000
      value
      10
    units
    Participants
description
Time to Progression (TTP): Time from start of therapy to meeting the definition of Progressive Disease (PD). PD: 25% increase compared to the lowest value of: * Serum MP (absolute increase at least ≥ 0.5 g/dl) * Or: Urine MP (absolute increase at least \> 200 mg/24h) * Or: for patients without measurable MP, Serum Free Light Chain test: the difference between involved and uninvolved FLC levels (absolute increase at least \>100 mg/L)
dispersion Type
Full Range
groups
  1. description
    Patients receive lenalidomide PO on days 1-21. Courses repeat every 28 days for 2 years or longer in the absence of disease progression or unacceptable toxicity. lenalidomide: Given PO
    id
    OG000
    title
    Treatment (Lenalidomide)
param Type
MEDIAN
population Description
Patients who developed Progressive Disease while on lenalidomide treatment
reporting Status
POSTED
time Frame
Up to 9 years
title
TTP
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice